Physician profile
Robert Christopher Van Winkle
NPI 1336129410
$5,077.54
in general payments reported to CMS, 2019-2025
27 companies · $1,042 in 2025
The $1,042 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,101 · 2020: $316 · 2021: $511 · 2022: $821 · 2023: $551 · 2024: $735 · 2025: $1,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,327.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,377.64 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $655.14 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $595.84 | 2019-2025 | |
| Glaxosmithkline, LLC. | $432.77 | 2019-2025 | Nucala |
| Kaleo, INC. | $402.69 | 2019-2024 | Auvi-Q |
| Optinose US, INC. | $393.39 | 2019-2025 | |
| Genzyme Corporation | $349.39 | 2019-2025 | |
| Amgen INC. | $136.56 | 2022-2024 | Tezspire |
| Genentech USA, INC. | $131.94 | 2019-2025 | Xolair |
| Pfizer INC. | $80.87 | 2019-2021 | |
| Greer Laboratories, INC. | $53.27 | 2025 | Oralair |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $49.07 | 2019-2021 | |
| Incyte Corporation | $48.17 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $48.12 | 2025 | Neffy |
| Organon LLC | $42.66 | 2025 | Vtama |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $40.02 | 2022-2023 | Adbry |
| Abbvie INC. | $36.20 | 2022-2023 | Rinvoq |
| Uswm, LLC | $31.95 | 2021 | |
| Alk-Abello, INC | $28.97 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $28.96 | 2022-2023 | Ryaltris |
| Sanofi-Aventis U.S. LLC | $22.07 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.95 | 2023 | Spiriva Respimat |
| Arcutis Biotherapeutics, INC. | $19.25 | 2025 | Zoryve |
| Eyevance Pharmaceuticals LLC | $14.15 | 2021 | |
| Lilly USA, LLC | $13.47 | 2024 | Ebglyss |
| Paratek Pharmaceuticals, INC. | $13.10 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Van Winkle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.